NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

CompletedPhase 2

Sponsor: AstraZeneca

Conditions: Breast Neoplasms

Interventions: Olaparib

Countries: United States, Australia, Canada, Germany, Israel, Spain, Sweden, United Kingdom

The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Advanced breast cancer with positive BRCA1 or BRCA2 status
* Failed at least one prior chemotherapy
* In investigators opinion, no curative standard therapy exists
* Measurable disease

Exclusion Criteria:

* Brain metastases
* Less than 28 days since last treatment used to treat the disease
* Considered a poor medical risk due to a serious uncontrolled disorder

Locations (17)

West Hollywood, California, United States
Boston, Massachusetts, United States
Melbourne, Australia
Randwick, Australia
Duarte, CA, Canada
Cologne, Germany
Kiel, Germany
München, Germany
Tel Aviv, Israel
Hospitalet deLlobregat, Spain
Madrid, Spain
Lund, Sweden
Cambridge, United Kingdom
Edinburgh, United Kingdom
Fulham, United Kingdom
London, United Kingdom
Manchester, United Kingdom